EAGLE EYE VISION
CITICOLIN SPRAY

• Citicolin (CDP-Cholin) ist eine wichtige körpereigene Substanz mit neuroprotektiver Wirkung, das heißt, sie schützt das Nervensystem. Es handelt sich um einen essenziellen Baustein für den Aufbau und die Reparatur von Zellmembranen. Zudem spielt Citicolin eine bedeutende Rolle bei der Bildung von Phosphatidylcholin, einem Hauptbestandteil (25–30%) der grauen Substanz im Gehirn.

• 40 ml Sprühflasche /entspricht 180 Sprühstößen

in allen Apotheken

pro 5 Sprühstösse (= Tagesbedarf):

• 500 mg CDP-Cholin
• 0,7 mg Vitamin B2 (Riboflavin)
• 0,7 mg Vitamin B6 (Pyridoxin)
• 0,1 mg Folsäure
• 1,25 μg Vitamin B12 (Cobalamin)
• 40,0 mg Vitamin C

1. Almasieh M, Wilson AM, Morquette B, et al. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res. 2012;31:152–181. doi: 10.1016/j.preteyeres.2011.11.002. [PubMed] [CrossRef] [Google Scholar]

2. Baudouin C, Labbé A, Liang H, et al. Preservatives in eye drops:the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–334. doi: 10.1016/j.preteyeres.2010.03.001. [PubMed] [CrossRef] [Google Scholar]

3. Carnevale C, Manni G, Roberti G, et al. Human vitreous concentrations of citicoline following topical application of citicoline 2% ophthalmic solution. PLoS ONE. 2019;14(2019):e0224982. doi: 10.1371/journal.pone.0224982. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Celiker H, Yuksel N, Solakoglu S, et al. Neuroprotective effects of memantine in the retina of glaucomatous rats: an electron microscopic study. J Ophthalmic Vis Res. 2016;11:174–182. doi: 10.4103/2008-322X.183934. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Chan MPY, Broadway DC, Khawaja AP, et al. Glaucoma and intraocular pressure in EPIC-Norfolk Eye Study: cross sectional study. BMJ. 2017;358:j3889. doi: 10.1136/bmj.j3889. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Dada T, Mittal D, Mohanty K, et al. Mindfulness meditation reduces intraocular pressure, lowers stress biomarkers and modulates gene expression in glaucoma: a randomized controlled trial. J Glaucoma. 2018;7:1061–1067. doi: 10.1097/IJG.0000000000001088. [PubMed] [CrossRef] [Google Scholar]

7. Dai H, Yin D, Hu C, et al. Whole-brain voxel-based analysis of diffusion tensor MRI parameters in patients with primary open angle glaucoma and correlation with clinical glaucoma stage. Neuroradiology. 2013;55:233–243. doi: 10.1007/s00234-012-1122-9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Engelhorn T, Michelson G, Waerntges S et al (2012) A new approach to assess intracranial white matter abnormalities in glaucoma patients: changes of fractional anisotropy detected by 3T diffusion tensor imaging. Acad Radiol 19:485-488 [PubMed]

9. Fadini GP, Pagano C, Baesso I, et al. Reduced endothelial progenitor cells and brachial artery flow- mediated dilation as evidence of endothelial dysfunction in ocular hypertension and primary open- angle glaucoma. Acta Ophthalmol. 2010;88:135–141. doi: 10.1111/j.1755- 3768.2009.01573.x. [PubMed] [CrossRef] [Google Scholar]

10. Fahy ET, Chrysostomou V, Crowston JG. Impaired axonal transport and glaucoma. Curr Eye Res. 2016;41:273–283. [PubMed] [Google Scholar]

11. Faiq MA, Dada T. Diabetes type 4: a paradigm shift in the understanding of glaucoma, the brain specific diabetes and the candidature of insulin as a therapeutic agent. Curr Mol Med. 2017;17:46–59. doi: 10.2174/1566524017666170206153415. [PubMed] [CrossRef] [Google Scholar]

12. Faiq MA, Wollstein G, Schuman JS, et al. Cholinergic nervous system and glaucoma: from basicscience to clinical applications. Prog Retin Eye Res. 2019;72:100767.doi: 10.1016/j.preteyeres.2019.06.003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005 doi: 10.1002/14651858.CD000269.pub3. [PubMed] [CrossRef] [Google Scholar]

14. Fogagnolo P, Melardi E, Tranchina L, et al. Topical citicoline and vitamin B12 versus placebo in the treatment of diabetes-related corneal nerve damage: a randomized double-blind controlled trial. BMC Ophthalmol. 2020;20:315. doi: 10.1186/s12886-020-01584-w. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Fresina M, Dickmann A, Salerni A, et al. Effect of oral CDP-choline on visual function in young amblyopic patients. Graefes Arch Clin Exp Ophthalmol. 2008;246:143–150. doi: 10.1007/s00417-007- 0621-6. [PubMed] [CrossRef] [Google Scholar]

16. Grieb P, Junemann A, Rekas M, et al. Citicoline: a food beneficial for patients suffering from or threated with glaucoma. Front Aging Neurosci. 2016 doi: 10.3389/fnagi.2016.00073. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013 doi: 10.1002/14651858.CD000980.pub4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Horn FK, Bergua A, Jünemann A, et al. Visual evoked potentials under luminance contrast and color contrast stimulation in glaucoma diagnosis. J Glaucoma. 2000;9:428–437. doi: 10.1097/00061198-200012000-00003. [PubMed] [CrossRef] [Google Scholar]

19. Ito YA, Di Polo A. Mitochondrial dynamics, transport, and quality control: a bottleneck for retinal ganglion cell viability in optic neuropathies. Mitochondrion. 2017;36:186–192. doi: 10.1016/j.mito.2017.08.014. [PubMed] [CrossRef] [Google Scholar]

20. Jain S, Aref AA. Senile dementia and glaucoma: evidence for a common link. J Ophthalmic Vis Res. 2014;10:178–183. [PMC free article] [PubMed] [Google Scholar]

21. Johnson TV, Bull ND, Martin KR. Neurotrophic factor delivery as a protective treatment for glaucoma. Exp Eye Res. 2011;93:196–203. doi: 10.1016/j.exer.2010.05.016. [PubMed] [CrossRef] [Google Scholar]

22. Jünemann A, Hohberger B, Rech J, et al. Agonistic Autoantibodies to the β2-Adrenergic receptor involved in the pathogenesis of open-angle glaucoma. Front Immunol. 2018;9:145. doi: 10.3389/fimmu.2018.00145. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Jünemann AGM, Huchzermeyer C, Rejdak R. Medikamentöse Glaukomtherapie – Welche Lehren können wir aus den großen klinischen Studien ziehen? Ophthalmologe. 2013;110:1134–1148. doi: 10.1007/s00347-012-2671-3. [PubMed] [CrossRef] [Google Scholar]

24. Krupinski J, Abudawood, Matou-Nasri S, et al. Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1. Vasc Cell. 2012;4:20. doi: 10.1186/2045-824X-4-20. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Lanza M, Gironi Carnevale UA, Mele L, et al. Morphological and functional evaluation of oral citicoline therapy in chronic open-angle glaucoma patients: A pilot study with a 2-year follow- up. Front Pharmacol. 2019;10:1117. doi: 10.3389/fphar.2019.01117. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Lee JY, Jeong HJ, Lee JH, et al. An investigation of lateral geniculate nucleus volume in patients with primary open-angle glaucoma using 7 T magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2014;55:3468–3476. doi: 10.1167/iovs.14-13902. [PubMed] [CrossRef] [Google Scholar]

27. Marino PF, Rossi GCM, Campagna G, et al. Effects of citicoline, homotaurine, and vitamin E on contrast sensitivity and visual-related quality of life in patients with primary open-angle glaucoma: a preliminary study. Molecules. 2020;25:5614. doi: 10.3390/molecules25235614. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

28. Michelson G, Engelhorn T, Wärntges S, et al. DTI parameters of axonal integrity and demyelination of the optic radiation correlate with glaucoma indices. Graefes Arch Clin Exp Ophthalmol. 2013;251:243–253. doi: 10.1007/s00417-011-1887-2. [PubMed] [CrossRef] [Google Scholar]

29. Mir C, Clotet J, Aledo R, et al. CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons. J Mol Neurosci. 2003;20:53–60. doi: 10.1385/JMN:20:1:53. [PubMed] [CrossRef] [Google Scholar]

30. Osborne NN, Chidlow G, Wood JP. Glutamate excitotoxicity in glaucoma: truth or fiction? By AJ Lotery. Eye. 2006;20:1392–1394. doi: 10.1038/sj.eye.6702234. [PubMed] [CrossRef] [Google Scholar]

31. Ottobelli L, Manni GL, Centofanti M, et al. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? Ophthalmologica. 2013;229:219–226. doi: 10.1159/000350496. [PubMed] [CrossRef] [Google Scholar]

32. Parisi V. Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5′-diphosphocholine (citicoline): a study of 8 years of follow-up. Doc Ophthalmol. 2005;110:91–102. doi: 10.1007/s10633-005-7348-7. [PubMed] [CrossRef] [Google Scholar]

33. Parisi V, Centofanti M, Ziccardi L, et al. Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2015;253:1327–1340. doi: 10.1007/s00417-015-3044-9. [PubMed] [CrossRef] [Google Scholar]

34. Parisi V, Coppola G, Centofanti M, et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res. 2008;173:541–554. doi: 10.1016/S0079-6123(08)01137-0. [PubMed] [CrossRef] [Google Scholar]

35. Parisi V, Coppola G, Ziccardi L, et al. Cytidine-5′-diphosphocholine (citicoline): a pilot study in patients with nonarteritic ischaemic optic neuropathy. Eur J Neurol. 2008;15:465–474. doi: 10.1111/j.1468-1331.2008.02099.x. [PubMed] [CrossRef] [Google Scholar]

36. Parisi V, Manni G, Colacino G, et al. Cytidine-5′-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. 1999;106:1126–1134. doi: 10.1016/S0161-6420(99)90269-5. [PubMed] [CrossRef] [Google Scholar]

37. Pecori-Giraldi J, Virno M, Covelli G, et al. Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation) Int Ophthalmol. 1989;13:109–112. doi: 10.1007/BF02028649. [PubMed] [CrossRef] [Google Scholar]

38. Pollak P. Fine chemicals: the industry and the business. 2. Hoboken: Willey; 2011. [Google Scholar]

39. Qian K, Gu Y, Zhao Y, et al. Citicoline protects brain against closed head injury in rats through suppressing oxidative stress and calpain over-activation. Neurochem Res. 2014;39:1206–1218. doi: 10.1007/s11064-014-1299-x. [PubMed] [CrossRef] [Google Scholar]

40. Rejdak R, Toczołowski J, Kurkowski J, et al. Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit. 2003;9:PI24–PI28. [PubMed] [Google Scholar]

41. Roberti G, Tanga L, Parisi V, et al. A preliminary study of the neuroprotective role of Citicoline eye drops in glaucomatous optic neuropathy. Indian J Ophthalmol. 2014;62:549–553. doi: 10.4103/0301- 4738.133484. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

42. Roda A, Fini A, Grigolo B, et al. Routes of administration and serum levels of [Methyl-14C]- Cytidine Diphosphocholine. Curr Ther Res. 1983;34:1049–1053. [Google Scholar]

43. Rossetti L, Iester M, Tranchina L, et al. Can treatment with citicoline eyedrops reduce progression in glaucoma? The results of a randomized placebo-controlled clinical trial. J Glaucoma. 2020;29:513–520. doi: 10.1097/IJG.0000000000001565. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

44. Schoemann J, Engelhorn T, Waerntges S, et al. Cerebral microinfarcts in primary open-angle glaucoma correlated with DTI-derived integrity of optic radiation. Invest Ophthalmol Vis Sci. 2014;55:7241–7247. doi: 10.1167/iovs.14-14919. [PubMed] [CrossRef] [Google Scholar]

45. Sen S, Saxena R, Tripathi M, et al. Neurodegeneration in Alzheimer’s disease and glaucoma: overlaps and missing links. Eye. 2020;34:1546–1553. doi: 10.1038/s41433-020-0836-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

46. Shekelle PG, Woolf SH, Eccles M, et al. Developing clinical guidelines. West J Med. 1999;170:348–351. [PMC free article] [PubMed] [Google Scholar]

47. Sun Y, Erdem E, Lyu A, et al. The SPARCS: A novel assessment of contrast sensitivity and its reliability in patients with corrected refractive error. Br J Ophthalmol. 2016;100:1421–1426. doi: 10.1136/bjophthalmol-2015-307378. [PubMed] [CrossRef] [Google Scholar]

48. Virno M, Pecori-Giraldi J, Liguori A, et al. The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up) Acta Ophthalmol Scand Suppl. 2000;232:56–57. doi: 10.1111/j.1600-0420.2000.tb01107.x. [PubMed] [CrossRef] [Google Scholar]

49. Wehrmann M. Vitamin C zum Schutz vor SARS-CoV-2 und zur Behandlung von COVID-19. J Gynäkol Endokrinol. 2020 doi: 10.1007/s41975-020-00155-y. [CrossRef] [Google Scholar]

50. Weinreb RN, Liebmann JM, Cioffi GA, et al. Oral memantine for the treatment of glaucoma: design and results of 2 randomized, placebo-controlled, phase 3 studies. Ophthalmology. 2018;125:1874– 1885. doi: 10.1016/j.ophtha.2018.06.017. [PubMed] [CrossRef] [Google Scholar]

51. Yildirim T, Eylen A, Lule S, et al. Poloxamer-188 and citicoline provide neuronal embrane integrity and protect membrane stability in cortical spreading depression. Int J Neurosci. 2015;125:941–946. doi: 10.3109/00207454.2014.979289. [PubMed] [CrossRef] [Google Scholar]

52. Zazueta C, Buelna-Chontal M, Macias-Lopez A, et al. Cytidine-5′-Diphosphocholine protects the liver from ischemia/reperfusion injury preserving mitochondrial function and reducing oxidative stress. Liver Transpl. 2018;24:1070–1083. doi: 10.1002/lt.25179. [PubMed] [CrossRef] [Google Scholar]

53. Zelefsky JR, Ritch R. Alternative and non-traditional treatments of glaucoma. In: Schacknow PN, Samples JR, editors. The Glaucoma Book. A Practical, Evidence-Based Approach to Patient Care. NewYork: Springer; 2010. pp. 657–669. [Google Scholar]

54. www.who.int/blindness/causes/en/